ArticleBritish journal of cancer2013
The impact of comorbidity and stage on prognosis of Danish melanoma patients, 1987-2009: a registry-based cohort study.
Article in British journal of cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 43 citations in OpenAlex.
- Oral glucocorticoid treatment for checkpoint inhibitor-associated inflammatory arthritis does not affect cancer progression-free survival: a RADIOS Registry study.Annals of the rheumatic diseases · 2026Observational
- Diabetes mellitus is associated with earlier detection of posterior uveal melanoma.European journal of ophthalmology · 2026Article
- Prognostic value of pretreatment neutrophil-to-lymphocyte ratio independent of comorbidity burden in melanoma.JAAD international · 2026Article
- Impact of comorbidities on survival in melanoma patients.BMC cancer · 2025Article
- The Characteristics of Sentinel Lymph Node Biopsy in Cutaneous Melanoma and the Particularities for Elderly Patients-Experience of a Single Clinic.Diagnostics (Basel, Switzerland) · 2023Article
- The role of imaging and sentinel lymph node biopsy in patients with T3b-T4b melanoma with clinically negative disease.Frontiers in oncology · 2023Article
- Article
- Association Between Underlying Comorbid Conditions and Stage of Presentation in Cutaneous Melanoma.Annals of surgical oncology · 2022Article
- Expression of Autoimmunity-Related Genes in Melanoma.Cancers · 2022Article
- A Cohort Study: Comorbidity and Stage Affected the Prognosis of Melanoma Patients in Taiwan.Frontiers in oncology · 2022Article
- Head and neck melanoma: outcome and predictors in a population-based cohort study.Head & face medicine · 2021Article
- Prevalence and risk factors for multimorbidity in older US patients with late-stage melanoma.Journal of geriatric oncology · 2021Article
- Real-World Experience of Talimogene Laherparepvec (T-VEC) in Old and Oldest-Old Patients with Melanoma: A Retrospective Single Center Study.Cancer management and research · 2021Article
- Improving management of comorbidity in patients with colorectal cancer using comprehensive medical assessment: a pilot study.BMC cancer · 2020Article
- Article
- Role, Extent, and Impact of Comorbidity on Prognosis and Survival in Advanced Metastatic Melanoma: A Review.The Journal of clinical and aesthetic dermatology · 2019Review
- Influence of socioeconomic factors and region of residence on cancer stage of malignant melanoma: a Danish nationwide population-based study.Clinical epidemiology · 2018Article
- The impact of patient comorbidity on cancer stage at diagnosis.British journal of cancer · 2015Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundComorbid conditions may play an important role in the prognosis of melanoma patients but have received little attention.
methodsUsing data from Danish registries, we identified patients diagnosed with melanoma from 1987 to 2009. We estimated the prevalence of comorbidity and calculated mortality rate ratios and interaction risks between melanoma and comorbidity. For every melanoma patient, 10 individuals were selected for comparison. Individuals in the comparison cohort were matched to their corresponding melanoma patients on age, gender, and exact prevalent comorbidities.
resultsWe included 23 476 patients, 81% of whom had no comorbidity. Higher prevalence of comorbidity was associated with more advanced cancer stage. The standardised mortality rate increased with increasing level of comorbidity in both cohorts and was consistently higher among melanoma patients. Melanoma and comorbidity interacted to increase the mortality rate. The highest proportional excess was seen in melanoma patients with comorbidity score 3, in whom interaction accounted for 77 deaths per 1000 person-years (40% of the total rate). We stratified by cancer stage and found that the interaction was markedly concentrated in patients with distant metastases.
conclusionInteraction between melanoma and comorbidity was primarily concentrated in patients with distant metastases, which raises the possibility that comorbidity is associated with delay of melanoma diagnosis, advanced cancer stage, and less aggressive melanoma treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.